Ga 68 PSMA-11 in BgRT: Targeting Bony Metastases in Prostate Cancer

Chunhui Han, PhD, medical physicist in the Department of Radiation Oncology at City of Hope National Medical Center, discusses the use of of Gallium 68 (Ga 68) PSMA-11 in biology-guided radiotherapy (BgRT) and whether or not the radiotracer can improve the targeting and treatment of bony metastases in patients with prostate cancer.

Ga 68 PSMA-11 is a radiotracer that was approved by the FDA in 2020. The agent works for imaging metastatic prostate cancer and targets the prostate-specific membrane antigen (PSMA), allowing for the detection of metastatic cancer cells throughout the body using PET scans.

He then moves on to discuss some of the known or potential adverse events associated with Ga 68 PSMA-11 that oncologists should be aware of.

Transcription:

0:10 | The use of Ga 68 could potentially facilitate treatment of bony metastatic status in prostate cancer. This study clearly demonstrated the feasibility of using Ga 68 PSMA-11 BgRT for bony metastasis. So, bony metastasis will light up and send a strong signal under the PET scan, and the RefleXion X1 machine uses a PET imaging system to detect signals from bony metastases when Ga 68 is injected, making it a potential candidate for BgRT.

1:13 | Ga 68 PSMA-11 is the first PSMA radiotracer approved by the FDA for PET imaging of [patients with] prostate cancer. There were no severe complications found in prior studies. However, there were some common complications associated with injection with Ga 68 PSMA-11, including nausea, diarrhea, and more as relatively minor complications.

1:56 | There is active research in the use of Ga 68 PSMA-11 for BgRT. The industry is actively evaluating the feasibility of Ga 68 PSMA-11 in BgRT treatments, and there is also active research at different centers, including City of Hope, on the availability of using Ga 68 PSMA-11 for prostate cancer bony metastasis.